Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. (WGS) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. GeneDx is a Delaware‑incorporated company whose Class A common stock trades on The Nasdaq Stock Market under the symbol WGS, with related warrants trading under WGSWW, as noted in its current reports on Form 8‑K.
Investors and analysts can use this page to review current reports on Form 8‑K, which for GeneDx have included announcements of quarterly financial results, updated guidance, and significant corporate events such as board appointments and annual meeting outcomes. These filings offer detail on revenue composition, exome and genome test volumes, margin metrics, cash position, and shareholder voting results, as described in the company’s earnings‑related 8‑K filings.
Because GeneDx positions itself as a global leader in rare disease diagnosis and rare disease genomics, its periodic and current reports are a key source for understanding how its genomic testing business, GeneDx Infinity dataset, and related initiatives translate into financial performance and corporate governance decisions. Filings also disclose information about securities such as its warrants, including listing details and exercise price.
On Stock Titan, SEC documents are paired with AI‑powered summaries that help explain the contents of lengthy filings in accessible language. Users can quickly see the main points from GeneDx’s 8‑K disclosures, and, where applicable, locate information related to quarterly and annual reporting, capital structure, and significant events affecting WGS shareholders. Real‑time updates from EDGAR ensure that new GeneDx filings appear promptly, while AI‑generated highlights make it easier to navigate complex regulatory documents.
GeneDx Holdings Corp. (WGS) insider filing shows CFO Kevin Feeley reported the vesting and settlement of 2,462 RSUs on 09/09/2025, which represent contingent rights to Class A common stock settled for $0 per share. To satisfy tax withholding on the settlement, the reporting person executed two sell transactions that disposed of 1,266 shares at $128.05 and 6 shares at $129.09. After these transactions Mr. Feeley beneficially owned 5,286 shares of Class A common stock directly, plus RSUs representing up to 131,830 shares and options covering 27,152 shares that vest per their terms.
GeneDx Holdings Corp. (WGS) Form 4 summary: The company's Chief Financial Officer received 717 restricted stock units (RSUs) that settled as Class A common stock and immediately caused a tax-withholding sale. A total of 378 shares were sold in a "sell-to-cover" transaction at a weighted-average price of $125.8096 per share to satisfy withholding obligations. After the transactions, the reporting person directly beneficially owned 4,096 shares of Class A common stock and retained RSUs and stock options representing potential future ownership of 134,292 RSU shares and 27,152 option shares, which vest per their terms. The disclosed RSU settlement indicates an ongoing compensation vesting schedule that vests 6.25% quarterly over four years from December 1, 2022.
Ryan Jason, a director of GeneDx Holdings Corp. (WGS), reported multiple open-market dispositions of Class A common stock on 08/27/2025. The Form 4 records seven separate sales totaling 39,222 shares (8,818; 8,969; 5,443; 3,452; 9,890; 1,500; 1,150) at weighted-average prices ranging roughly from $124.50 to $130.19 per share. After these transactions, the filing shows beneficial ownership positions reported as indirect through the "Jason Ryan 2024 GRAT," with the largest reported post-transaction position at 132,538 shares and the smallest at 11,904 shares; one line shows 103,284 shares directly or indirectly owned. The filing discloses that Jason Ryan is trustee and sole annuitant of the GRAT and remains the beneficial owner of securities held by the trust.
GeneDx Holdings Corp. (WGS) filing a Form 144 notifies the market that 39,222 shares of common stock are proposed for sale on 08/27/2025 through Merrill Lynch on Nasdaq, with an aggregate market value of $4,990,000. The company reports 28,726,248 shares outstanding, so the sale represents a small portion of the outstanding shares.
The shares to be sold were acquired in two tranches: 38,072 shares bought on the open market on 12/31/2023 for cash, and 1,150 shares from RSU vesting on 06/18/2025. No securities were reported sold by the selling person in the past three months. The filer attests there is no undisclosed material adverse information.
Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.
The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.
Form 144 notice for GeneDx Holdings Corp. (symbol WGS) documents a proposed sale of 500,000 shares of Class A common stock through Jefferies LLC, with an aggregate market value of $60,451,950 and an approximate sale date of 08/22/2025 on NASDAQ. The filing states the shares were purchased from the issuer on 01/27/2023 for cash. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer. The filing does not name the selling person or provide additional context about ownership or intent.
Casdin-related parties reported insider sales of GeneDx Holdings Corp. (WGS) common stock on 08/22/2025. The filing shows a sale of 500,000 shares of Class A common stock at $120.9039 per share. After the reported transactions, the group reports beneficial ownership of 3,007,164 shares on an indirect basis. The Form 4 lists additional holdings and dispositions across related entities and individuals, including direct ownership of 20,518 shares and indirect positions of 19,247 and 333,144 shares, with explanatory footnotes describing relationships among Casdin Capital, Casdin Partners funds, the GP and Eli Casdin.
Summit Partners and affiliated entities reported beneficial ownership of 867,265 shares of GeneDx Holdings Corp. Class A common stock, representing 3.04% of the outstanding shares based on 28,553,204 common shares used for the calculation. The holdings are aggregated across several funds and accounts managed by Summit Partners Public Asset Management (SPPAM), with Summit Partners, L.P. serving as the managing member.
The filing shows the group has 0 sole voting power, 771,333 shares subject to shared voting power and 867,265 shares subject to shared dispositive power. SPPAM is identified as the investment manager for the funds holding the positions. The reporting persons state the securities were not acquired to influence control and the filing is made under a joint filing agreement with powers of attorney for certain signatories.
GeneDx Holdings (WGS) – Amended Form 4 (filed 08-07-25)
Director and 10 % owner Eli Casdin reported the vesting and immediate settlement of 12,924 RSUs on 06-18-25, converting to Class A common shares at $0 exercise cost. Following the event, Casdin now holds 20,518 shares directly and, through various affiliated entities, 3.86 million shares indirectly (3,507,164 via Casdin Partners Master Fund LP, 333,144 via CMLS Holdings LLC, and 19,247 via Casdin Partners GP LLC).
The amendment corrects prior clerical errors: earlier filings over-stated direct holdings by 1,376 shares and under-stated them by 4,452 shares in separate periods. No open-market purchases or sales occurred; transactions solely reflect RSU vesting. The RSUs will continue to vest on the earlier of the next annual meeting or one-year anniversary, contingent on service.
Investor takeaway: The filing increases disclosure accuracy but does not involve cash transactions or alter the overall economic exposure of this significant insider.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
